SION - NASDAQ
Sionna Therapeutics, Inc.
$36.70
-10%Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
At a Glance
Live Snapshotsion
Other Current Liabilities
Last Annual Value
9.67M
3-Year CAGR
70%
5-Year CAGR
38%
10-Year CAGR
17%
Sionna Therapeutics, Inc. Competitors Analysis of Other Current Liabilities
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Sionna Therapeutics, Inc. NASDAQ:SION | 9.67M | 45.9% | N/A | N/A | |
 Vera Therapeutics, Inc. NASDAQ:VERA | 31.01M | 86.0% | 141.6% | N/A | |
 Janux Therapeutics, Inc. NASDAQ:JANX | 13.04M | 58.1% | 40.6% | N/A | |
 Maze Therapeutics, Inc. NASDAQ:MAZE | 15.97M | 76.1% | N/A | N/A | |
 Ardelyx, Inc. NASDAQ:ARDX | 66.69M | 64.3% | 121.8% | 20.4% | |
 Celldex Therapeutics, Inc. NASDAQ:CLDX | 48.26M | 129.6% | 98.8% | 6.2% | |
 Immunome, Inc. NASDAQ:IMNM | 41.65M | 103.0% | 83.2% | N/A | |
 Xeris Biopharma Holdings, Inc. NASDAQ:XERS | 100.27M | 24.9% | 31.4% | 71.0% | |
 Biohaven Ltd. NYSE:BHVN | 104.29M | N/A | N/A | N/A |
Sionna Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your SION research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.